Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses

Archives of Internal Medicine

Volumn 164, Issue 1, 2004, Pages 40-44

  Hennekens, Charles H ^a,b   Sacks, Frank M ^a,c   Tonkin, Andrew ^a,d   Jukema, J Wouter ^e   Byington, Robert P ^a,f   Pitt, Bertram ^a,g   Berry, Donald A ^h,i   Berry, Scott M ^a,i   Ford, Neville F ^a,j   Walker, Andrew J ^a   Natarajan, Kannan ^a   Sheng Lin, Chen ^a   Fiedorek, Frederick T ^a   Belder, Rene ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NATIONAL HEART FOUNDATION OF AUSTRALIA   (Australia)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f WAKE FOREST UNIVERSITY   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ Berry Associates   (United States)

^j Woodfield Clinical Consulting LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT; PRAVASTATIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG COMBINATION; DRUG EFFICACY; FATALITY; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 9144235516     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.1.40     Document Type: Article

References (32)

1. Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
2. Sacks FM, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1019.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Hobert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs: risk of stroke and total mortality. JAMA. 1997;278:313-321.
5. Elwood PC, Cochrane AL, Bur ML, et al. A randomised controlled trial of acetyl-salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436-440.
6. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979;2:1313-1315.
7. Aspirin Myocardial Infarction Study Research Group. The Aspirin Myocardial Infarction Study: final results. Circulation. 1980;62(suppl 5):V79-V84.
8. Coronary Drug Project (CDP) Research Group. Aspirin in coronary heart disease. J Chronic Dis. 1976;29:625-642.
9. Breddin K, Loew D, Lechner K, et al, for the German-Austrian Study Group. The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. Circulation. 1980;62(suppl 5):V63-V72.
10. Vogel G, Fischer C, Huyke R. Reinfarktprophylaxe mit azetylsalizylsaure. Folia Haematol (Leipz). 1979;106:797-803.
11. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
12. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients: Antithrombotic Trialists' Collaboration (ATT) [published erratum appears in BMJ. 2002; 324:141]. BMJ. 2002;324:71-86.
13. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients: Antithrombotic Trialists' Collaboration (ATT) [published erratum appears in BMJ. 2002; 324:141]. BMJ. 2002;324:71-86.
14. CDER new and generic drug approvals: 1998-2003. Available at: http://www.fda.gov/cder/approval/index.htm.
15. 64 Federal Register 49653 (1999) (codified at 21 CFR §343.80).
16. Hebert PR, Pfeffer MA, Hennekens CH. Use of statins and aspirin to reduce risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2002;7:77-80.
17. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
18. Hennekens CH, Dyken M, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96:2751-2753.
19. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation. 2001;104:1577-1579.
20. Beller GA. ACC presidential address: quality of cardiovascular care in the US. J Am Coll Cardiol. 2001;38:587-594.
21. Pearson TA, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP). Arch Intern Med. 2000;160:459-467.
22. Cook NR, Chae C, Mueller FB, Landis S, Saks AM, Hennekens CH. Mismedication and under-utilization of aspirin in the prevention and treatment of cardiovascular disease. MedGenMed [serial online]. November 22,1999; e1. Available at: http://www.medscape.com.
23. Califf RM, Delong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. Am J Cardiol. 2002;89:653-661.
24. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
25. Pitt B, Mancini GB, Ellis SG, et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol. 1995;26:1133-1139.
26. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
27. Stangl DK, Berry DA. Meta-analysis in Medicine and Health Policy. New York, NY: Marcel Dekker Inc; 2000.
28. Ridker PM, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839-844.
29. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
30. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
31. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, Mass: Little Brown & Co Inc; 1987.
32. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey: 1988-94. Hyattsville, Md: Vital Health Statistics, US Dept of Health and Human Services; 1994. Series 1, No. 32. DHHS publication PHS 94-1308.